Telzuit Medical Technologies: Recent Update Call

ORLANDO, FL, Jan 22 (MARKET WIRE) --
Telzuit (OTCBB: TZMT) initiated a conference call on Monday, January 21, 2008
at
2:00 PM Eastern Time to update investors on the Company. To listen to a replay
of the call, please dial 1-888-899-7904. The playback ID# is 082821021. The
following contains an outline of what was said on the call:

-- During the past year we have improved and perfected the operation of
the StatPatch by enhancing components on the circuit board and reducing the
cost of manufacturing.

-- We have moved the software platform for the StatPatch from the Palm
operating system to Windows mobile 5.0 and most recently to Windows Mobile
6.0.

-- We have significantly improved the Bluetooth operating range of the
StatPatch resulting in fewer drops.

-- We created a PC version of the software for institutional use.

-- We improved the PDA software so that the OEM battery will now complete
a 24 hour Holter test without the need to recharge the battery.

-- We have run some 500 tests this year with the StatPatch system and
have a 97% success rate.

-- We believe that the failure rate of the traditional wired Holter is
much greater than our 3%. Perhaps as high as 30%.

-- Our use of the StatPatch on patients has been successfully paid for by
Medicare and other third party payers.

-- The Cardiologist reviewing the StatPatch tests and interpreting the
results via a written report back to the physicians ordering the Holter has
found the StatPatch recordings to be of excellent quality, accurate and
exceedingly easy to evaluate and interpret. The Cardiologist also believes
that the StatPatch is more efficient than other technology out there now.

-- We have reduced the cash burn rate of the company from over $400k per
month to under $100k per month.

-- Component changes and manufacturing efficiencies will reduce the
overall cost of the StatPatch and yield us an improved profit margin. Also,
PDA acquisition costs have been reduced by 60%.

-- We have distribution agreements in progress to hit the ground running
as soon as there is enough funding to start building sufficient inventory
of the StatPatch.

-- We are in substantive discussions with a foreign provider if EKG
products and services to serve as their OEM for wireless holter monitors
and related products. This third party will have rights to our product in
Europe and selected US markets, if we successfully complete this
partnership. We believe that if successfully completed this partnership
will provide the company with sales levels that are substantial.

-- We have begun discussions with one of the largest distributors of EKG
products in the US to serve as our distributor in selected US markets.

-- To sum up, the product is ready to tackle the holter monitoring
market. We believe we have the relationships in place or nearly in place
that will enable us to achieve substantial penetration. We currently lack
the financial resources to fulfill this plan.

-- On a related note we intend to make strategic additions to the Board
of Directors. Kenneth Adams and Richard Bischoff have resigned from the
Board to make way for future additions.

About Telzuit Medical Technologies, Inc.

Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile
medicine to patients. The STATPATCH System is a full 12-lead, completely
wireless
Holter monitor. The STATPATCH System has been approved by the FDA under a 510-K
filing. Telzuit also provides ultrasound medical imaging services to physicians
in Central Florida through six mobile imaging units. Telzuit is based in
Orlando. For more information about Telzuit, its business model and its
products, please visit the Company's web site: http://www.telzuit.com

Forward-Looking Statements: Except for factual statements made herein, the
information contained in this press release consists of forward-looking
statements that
involve risks and uncertainties, including the effect of changing economic
conditions, competition within the health products industry, customer acceptance
of products, and other risks and uncertainties. Such forward-looking
statements are not guarantees of performance, and Telzuit results could
differ materially from those contained in such statements. These
forward-looking statements speak only as of the date of this release, and
Telzuit undertakes no obligation to publicly update any forward-looking
statements to reflect new information, events or circumstances after the date of
this
release.

Contact:

Jerry Balter
Chief Financial Officer
Telzuit Medical Technologies, Inc.
407-354-1222

Copyright 2008, Market Wire, All rights reserved.

-0-